{
    "clinical_study": {
        "@rank": "102666", 
        "arm_group": {
            "arm_group_label": "patients with bone dominant metastatic ER+ breast cancer"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the utility of FDG PET/CT in evaluating response of\n      bone dominant breast cancer to therapy. Eligible patients with bone dominant ER+ breast\n      cancer will undergo baseline FDG PET/CT for evaluation of their disease, after the start of\n      therapy they will undergo an FDG PET/CT scan at 4 weeks and again at 12 weeks. PET/CT\n      results will be compared to clinical measures of response, time to progression and overall\n      survival."
        }, 
        "brief_title": "18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Bone Dominant Metastatic ER+ Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, at least 18 years of age, with a history of pathologically confirmed\n             ER+ breast cancer\n\n          -  Biopsy proven or clinically obvious documented bone metastases from breast cancer\n             (with the majority of the disease burden in the bone)\n\n          -  Patients planning to start new endocrine targeted therapy (any line of therapy is\n             acceptable and any endocrine therapy is allowed)\n\n          -  Willing and able to comply with scheduled visits and serial imaging procedures\n\n          -  Agrees to allow access to clinical records regarding response to treatment and long\n             term follow up 6. Be informed of the investigational nature of this study and provide\n             written informed consent in accordance with institutional and federal guidelines.\n\n        Exclusion Criteria\n\n          -  Women who are pregnant or breast feeding\n\n          -  Uncontrolled diabetes mellitus (fasting glucose greater than 200 mg/dL)\n\n          -  Inability to tolerate imaging procedures (e.g. claustrophobia, severe pain)\n\n          -  Weight exceeding capacity of imaging table\n\n          -  Previous treatment with radiation or surgery to a significant percentage of bony\n             metastatic sites 6. Treatment with marrow stimulating agents (e.g. granulocyte colony\n             stimulating factor (GCSF)) within 3 weeks of baseline scan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "A total of up to 75 subjects, age 18 years, with a diagnosis or estrogen receptor positive\n        (ER+) breast cancer, with clinical evidence of bone dominant stage IV disease will be\n        enrolled in this study. This study will enroll both women and men but it is anticipate\n        that the majority of subjects will be women due to the small percentage of breast cancer\n        patients that are male."
            }
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02110160", 
            "org_study_id": "UPCC 17113"
        }, 
        "intervention": [
            {
                "arm_group_label": "patients with bone dominant metastatic ER+ breast cancer", 
                "intervention_name": "FDG PET/CT", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "patients with bone dominant metastatic ER+ breast cancer", 
                "intervention_name": "Fluorodeoxyglucose F 18 Injection (FDG)", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Deoxyglucose"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "David Mankoff, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "David Mankoff, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "David A. Mankoff, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "David Mankoff, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02110160"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}